Quinoxaline

Quinoxaline

SCHEMBL1335895

NC=O.c1ccc2nccnc2c1

nearest known ligand 0.44

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.44
NCF1 P14598 1/20 0.43
LOXL2 Q9Y4K0 1/20 0.40
MAPT P10636 7/20 0.37
NPC1 O15118 3/20 0.37
RAB9A P51151 3/20 0.37
TP53 P04637 1/20 0.37
PTK2B Q14289 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
KDM4E B2RXH2 3/20 0.37
KMT2A Q03164 3/20 0.37
MEN1 O00255 2/20 0.37
USP2 O75604 1/20 0.37
POLB P06746 1/20 0.37
HPGD P15428 2/20 0.36
HSD17B10 Q99714 2/20 0.36
GAA P10253 1/20 0.36
ERN1 O75460 2/20 0.35
HDAC3 O15379 1/20 0.35
HDAC4 P56524 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Formamide SCHEMBL27359672 0.90 ALDH1A1 (0.50) ALDH1A1NCF1MAPTNPC1RAB9A
Biphenyl SCHEMBL29090175 0.84 ALDH1A1 (0.46) ALDH1A1NCF1MAPTNPC1RAB9A
Quinoxaline SCHEMBL27509310 0.84 ALDH1A1 (0.44) ALDH1A1NCF1LOXL2MAPTNPC1
Quinoxaline SCHEMBL8335477 0.84 ALDH1A1 (0.44) ALDH1A1NCF1LOXL2MAPTNPC1
Quinoxaline SCHEMBL27373524 0.84 ALDH1A1 (0.44) ALDH1A1NCF1LOXL2MAPTNPC1
Quinoxaline SCHEMBL28804078 0.83 ALDH1A1 (0.39) ALDH1A1NCF1LOXL2MAPTNPC1
Quinoxaline SCHEMBL30320908 0.83 ALDH1A1 (0.58) ALDH1A1NCF1LOXL2MAPTKDM4E
Quinoxaline SCHEMBL6928518 0.83 ALDH1A1 (0.58) ALDH1A1NCF1LOXL2MAPTKDM4E
Quinoxaline SCHEMBL5315 0.83 ALDH1A1 (0.58) ALDH1A1NCF1LOXL2MAPTKDM4E
Quinoxaline SCHEMBL29355228 0.83 ALDH1A1 (0.58) ALDH1A1NCF1LOXL2MAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108138177-B The combination of Dbait molecule and PARP inhibitor is used for the purposes for the treatment of cancer 法国居里学院 2019-03-19 CN disclosed
CN-108138177-A The combination of Dbait molecules and PARP inhibitor is used for the purposes for the treatment of cancer 法国居里学院 2018-06-08 CN disclosed
US-20110275643-A1 AROYLQUINOLINE COMPOUNDS NATIONAL HEALTH RESEARCH INSTITUTES (TW) 2011-11-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110275643-A1 AROYLQUINOLINE COMPOUNDS TUBA1C, TUBB1, TUBB3 ALDH1A1 657/4885NCF1 1427/4885LOXL2 4366/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.